tag :: DISCLOSURE | BibSonomy

bookmarks (hide)2
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

publications (hide)52
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...

1Corporate Information Disclosure and Stock Market Valuation? A Dummy Variable Regresssion Approach
E. Ekene. International Journal on Economics, Finance and Sustainable Development (IJEFSD), 5 (6): 186-198 (June 2023)
a year ago by @researchpark_20
show all tags
Corporate
accounting
all
and
disclosure
disclosure,
index
information
information,
mode
of
quality
share
stock
timely
valuation,
Corporateaccountingallanddisclosuredisclosure,indexinformationinformation,modeofqualitysharestocktimelyvaluation,
(0)
copydeleteadd this publication to your clipboard
1Board Characteristics and Environmental Remediation Disclosure of Listed Oil and Gas Firms in Nigeria and South Africa
E. Mbonu, Chikwelu Maduabuchi | Okoye. INTERNATIONAL JOURNAL OF TREND IN SCIENTIFIC RESEARCH AND DEVELOPMENT, 7 (3): 303-309 (June 2023)
a year ago by @ijtsrd
show all tags
Committee
Concentration,
Disclosure
Environmental
Ownership
Remediation
Size,
auditing
CommitteeConcentration,DisclosureEnvironmentalOwnershipRemediationSize,auditing
(0)
copydeleteadd this publication to your clipboard
1Leaping to conclusions.
M. McCartney. BMJ (Clinical research ed.), 336 (7655): 1213-4 (May 2008)4673<m:linebreak></m:linebreak>LR: 20081120; JID: 8900488; OID: NLM: PMC2405859; ppublish;<m:linebreak></m:linebreak>Anàlisi de dades.
2 years ago by @jepcastel
show all tags
ClinicalTrialsasTopic
ClinicalTrialsasTopic:methods
DataCollection
Disclosure
Evidence-BasedMedicine
Humans
ReviewLiteratureasTopic
ClinicalTrialsasTopicClinicalTrialsasTopic:methodsDataCollectionDisclosureEvidence-BasedMedicineHumansReviewLiteratureasTopic
(0)
copydeleteadd this publication to your clipboard
1Reformulating the hazard ratio to enhance communication with clinical investigators.
M. Buyse. Clinical trials (London, England), 5 (6): 641-2 (January 2008)4679<m:linebreak></m:linebreak>JID: 101197451; ppublish;<m:linebreak></m:linebreak>Anàlisi de supervivència.
2 years ago by @jepcastel
show all tags
Bias(Epidemiology)
ClinicalTrialsasTopic
Disclosure
Humans
LogisticModels
ProportionalHazardsModels
ReproducibilityofResults
RiskAssessment
Bias(Epidemiology)ClinicalTrialsasTopicDisclosureHumansLogisticModelsProportionalHazardsModelsReproducibilityofResultsRiskAssessment
(0)
copydeleteadd this publication to your clipboard
1Varieties of uncertainty and the validity of informed consent.
K. Weinfurt. Clinical trials (London, England), 5 (6): 624-5; discussion 630 (January 2008)4680<m:linebreak></m:linebreak>GR: 5R01CA100771-04/CA/NCI NIH HHS/United States; JID: 101197451; ppublish;<m:linebreak></m:linebreak>Data protection.
2 years ago by @jepcastel
show all tags
ClinicalTrials
Disclosure
Humans
InformedConsent
InformedConsent:ethics
InformedConsent:psychology
Neoplasms
Neoplasms:drugtherapy
Neoplasms:psychology
PatientEducationasTopic
PhaseIasTopic
PhaseIasTopic:ethics
PhaseIasTopic:psychology
RiskAssessment
Uncertainty
ClinicalTrialsDisclosureHumansInformedConsentInformedConsent:ethicsInformedConsent:psychologyNeoplasmsNeoplasms:drugtherapyNeoplasms:psychologyPatientEducationasTopicPhaseIasTopicPhaseIasTopic:ethicsPhaseIasTopic:psychologyRiskAssessmentUncertainty
(0)
copydeleteadd this publication to your clipboard
1Medicine. Moving toward transparency of clinical trials.
D. Zarin, and T. Tse. Science (New York, N.Y.), 319 (5868): 1340-2 (March 2008)4974<m:linebreak></m:linebreak>LR: 20081120; GR: NIH0010298972/PHS HHS/United States; JID: 0404511; CIN: Science. 2008 Oct 3;322(5898):44-6. PMID: 18832629; NIHMS41213; OID: NLM: NIHMS41213; OID: NLM: PMC2396952; ppublish;<m:linebreak></m:linebreak>Recursos/Organització; Recerca clínica.
2 years ago by @jepcastel
show all tags
AccesstoInformation
AdverseDrugReactionReportingSystems
ClinicalTrialsasTopic
ClinicalTrialsasTopic:legislation&jurisprude
ClinicalTrialsasTopic:standards
Databases
Disclosure
Factual
Humans
IntellectualProperty
Postmarketing
ProductSurveillance
PublicPolicy
Publishing
Registries
UnitedStates
UnitedStatesFoodandDrugAdministration
UnitedStatesFoodandDrugAdministration:legisl
AccesstoInformationAdverseDrugReactionReportingSystemsClinicalTrialsasTopicClinicalTrialsasTopic:legislation&jurisprudeClinicalTrialsasTopic:standardsDatabasesDisclosureFactualHumansIntellectualPropertyPostmarketingProductSurveillancePublicPolicyPublishingRegistriesUnitedStatesUnitedStatesFoodandDrugAdministrationUnitedStatesFoodandDrugAdministration:legisl
(0)
copydeleteadd this publication to your clipboard
1Design of clinical trials.
D. Rollo, S. Machado, and M. Ceschin. Seminars in nuclear medicine, 40 (5): 332-7 (September 2010)5927<m:linebreak></m:linebreak>CI: Copyright 2010; JID: 1264464; 0 (Radiopharmaceuticals); ppublish;<m:linebreak></m:linebreak>Disseny; Tipus d'estudis; RCT.
2 years ago by @jepcastel
show all tags
Bias(Epidemiology)
ClinicalTrialsasTopic
ClinicalTrialsasTopic:methods
DiagnosticImaging
Disclosure
Drug-RelatedSideEffectsandAdverseReactions
DrugLabeling
EarlyTerminationofClinicalTrials
EpidemiologicResearchDesign
Humans
NuclearMedicine
NuclearMedicine:methods
Radiopharmaceuticals
Radiopharmaceuticals:adverseeffects
Radiopharmaceuticals:diagnosticuse
Radiopharmaceuticals:economics
Radiopharmaceuticals:supply&distribution
ResearchDesign
SocialResponsibility
TimeFactors
Bias(Epidemiology)ClinicalTrialsasTopicClinicalTrialsasTopic:methodsDiagnosticImagingDisclosureDrug-RelatedSideEffectsandAdverseReactionsDrugLabelingEarlyTerminationofClinicalTrialsEpidemiologicResearchDesignHumansNuclearMedicineNuclearMedicine:methodsRadiopharmaceuticalsRadiopharmaceuticals:adverseeffectsRadiopharmaceuticals:diagnosticuseRadiopharmaceuticals:economicsRadiopharmaceuticals:supply&distributionResearchDesignSocialResponsibilityTimeFactors
(0)
copydeleteadd this publication to your clipboard
1Research protocols: waiving confidentiality for the greater good.
A. Chan, R. Upshur, J. Singh, D. Ghersi, F. Chapuis, and D. Altman. BMJ (Clinical research ed.), 332 (7549): 1086-9 (May 2006)4241<m:linebreak></m:linebreak>LR: 20070116; PUBM: Print; JID: 8900488; RF: 24; OID: KIE: 130260; OTO: KIE; GN: KIE: KIE Bib: biomedical research; confidentiality; human experimentation/ethics committees; ppublish;<m:linebreak></m:linebreak>Tipus d'estudis.
2 years ago by @jepcastel
show all tags
ClinicalProtocols
ClinicalTrialsasTopic
Confidentiality
Disclosure
EthicsCommittees
Publishing
ClinicalProtocolsClinicalTrialsasTopicConfidentialityDisclosureEthicsCommitteesPublishing
(0)
copydeleteadd this publication to your clipboard
2The ADVANTAGE seeding trial: a review of internal documents.
K. Hill, J. Ross, D. Egilman, and H. Krumholz. Annals of internal medicine, 149 (4): 251-8 (August 2008)4606<m:linebreak></m:linebreak>LR: 20081203; JID: 0372351; 0 (Cyclooxygenase 2 Inhibitors); 0 (Lactones); 0 (Sulfones); 0 (rofecoxib); CIN: Ann Intern Med. 2008 Aug 19;149(4):279-80. PMID: 18711161; CIN: Ann Intern Med. 2008 Nov 18;149(10):773; author reply 773-4. PMID: 19017606; CIN: Ann Intern Med. 2008 Nov 18;149(10):774. PMID: 19017608; RF: 32; ppublish;<m:linebreak></m:linebreak>Tipus d'estudis; Seeding trials.
2 years ago by @jepcastel
show all tags
ClinicalTrialsasTopic
ClinicalTrialsasTopic:ethics
ClinicalTrialsasTopic:standards
ConflictofInterest
Cyclooxygenase2Inhibitors
Cyclooxygenase2Inhibitors:adverseeffects
Cyclooxygenase2Inhibitors:therapeuticuse
Deception
Disclosure
DrugIndustry
DrugIndustry:ethics
EthicsCommittees
GastrointestinalDiseases
GastrointestinalDiseases:chemicallyinduced
Humans
Lactones
Lactones:adverseeffects
Lactones:therapeuticuse
Marketing
Marketing:ethics
Research
Sulfones
Sulfones:adverseeffects
Sulfones:therapeuticuse
ClinicalTrialsasTopicClinicalTrialsasTopic:ethicsClinicalTrialsasTopic:standardsConflictofInterestCyclooxygenase2InhibitorsCyclooxygenase2Inhibitors:adverseeffectsCyclooxygenase2Inhibitors:therapeuticuseDeceptionDisclosureDrugIndustryDrugIndustry:ethicsEthicsCommitteesGastrointestinalDiseasesGastrointestinalDiseases:chemicallyinducedHumansLactonesLactones:adverseeffectsLactones:therapeuticuseMarketingMarketing:ethicsResearchSulfonesSulfones:adverseeffectsSulfones:therapeuticuse
(0)
copydeleteadd this publication to your clipboard
1The continuing unethical conduct of underpowered clinical trials.
S. Halpern, J. Karlawish, and J. Berlin. JAMA : the journal of the American Medical Association, 288 (3): 358-62 (July 2002)3459<m:linebreak></m:linebreak>Mesures de contrast.
2 years ago by @jepcastel
show all tags
Bias(Epidemiology)
Clinical
ClinicalTrialsasTopic
ClinicalTrialsasTopic:standards
ClinicalTrialsasTopic:statistics&numericald
Disclosure
Ethics
Humans
InformedConsent
Meta-AnalysisasTopic
ReproducibilityofResults
ResearchDesign
Bias(Epidemiology)ClinicalClinicalTrialsasTopicClinicalTrialsasTopic:standardsClinicalTrialsasTopic:statistics&numericaldDisclosureEthicsHumansInformedConsentMeta-AnalysisasTopicReproducibilityofResultsResearchDesign
(0)
copydeleteadd this publication to your clipboard
1Declaration of transparency for each research article.
D. Altman, and D. Moher. BMJ (Clinical research ed.), (January 2013)7500<m:linebreak></m:linebreak>JID: 8900488; OID: NLM: PMC3737035; epublish;<m:linebreak></m:linebreak>Publicació.
2 years ago by @jepcastel
show all tags
BiomedicalResearch
BiomedicalResearch:ethics
Disclosure
Disclosure:standards
PeriodicalsasTopic
PeriodicalsasTopic:standards
Publishing
Publishing:ethics
Publishing:standards
ResearchDesign
BiomedicalResearchBiomedicalResearch:ethicsDisclosureDisclosure:standardsPeriodicalsasTopicPeriodicalsasTopic:standardsPublishingPublishing:ethicsPublishing:standardsResearchDesign
(0)
copydeleteadd this publication to your clipboard
1The influence of money on medical science.
C. DeAngelis. JAMA : the journal of the American Medical Association, 296 (8): 996-8 (August 2006)4269<m:linebreak></m:linebreak>LR: 20071115; PUBM: Print-Electronic; DEP: 20060807; JID: 7501160; CIN: JAMA. 2006 Dec 27;296(24):2925-6; author reply 2926. PMID: 17190892; 2006/08/07 aheadofprint; ppublish;<m:linebreak></m:linebreak>Publicació.
2 years ago by @jepcastel
show all tags
BiomedicalResearch
BiomedicalResearch:economics
BiomedicalResearch:ethics
Commerce
ConflictofInterest
Disclosure
EditorialPolicies
Industry
PeerReview
Research
ResearchSupportasTopic
ResearchSupportasTopic:ethics
BiomedicalResearchBiomedicalResearch:economicsBiomedicalResearch:ethicsCommerceConflictofInterestDisclosureEditorialPoliciesIndustryPeerReviewResearchResearchSupportasTopicResearchSupportasTopic:ethics
(0)
copydeleteadd this publication to your clipboard
1Genetic and molecular epidemiology.
J. Ioannidis. Journal of epidemiology and community health, 61 (9): 757-8 (September 2007)4641<m:linebreak></m:linebreak>JID: 7909766; ppublish;<m:linebreak></m:linebreak>Epidemiologia genètica.
2 years ago by @jepcastel
show all tags
Disclosure
EnvironmentalExposure
EpidemiologicStudies
Genetics
Genome
Greece
Human
Humans
Medical
MolecularEpidemiology
RCT
DisclosureEnvironmentalExposureEpidemiologicStudiesGeneticsGenomeGreeceHumanHumansMedicalMolecularEpidemiologyRCT
(0)
copydeleteadd this publication to your clipboard
1Guidelines for reporting mortality and morbidity after cardiac valve interventions.
C. Akins, D. Miller, M. Turina, N. Kouchoukos, E. Blackstone, G. Grunkemeier, J. Takkenberg, T. David, E. Butchart, D. Adams and 4 other author(s). The Journal of thoracic and cardiovascular surgery, 135 (4): 732-8 (April 2008)Publicació; Anàlisi de dades; CV; Cirurgia.
2 years ago by @jepcastel
show all tags
Adult
CardiacSurgicalProcedures
CardiacSurgicalProcedures:methods
CardiacSurgicalProcedures:mortality
CardiacSurgicalProcedures:statistics&numerica
Child
Disclosure
Disclosure:standards
GuidelinesasTopic
HeartValveDiseases
HeartValveDiseases:surgery
Humans
Morbidity
AdultCardiacSurgicalProceduresCardiacSurgicalProcedures:methodsCardiacSurgicalProcedures:mortalityCardiacSurgicalProcedures:statistics&numericaChildDisclosureDisclosure:standardsGuidelinesasTopicHeartValveDiseasesHeartValveDiseases:surgeryHumansMorbidity
(0)
copydeleteadd this publication to your clipboard
1The Ripple Effect of EU Disclosures Regulation in Financial Services Sector
C. Malecki. BOHR International Journal of Business Ethics and Corporate Governance, 1 (1): 69-75 (August 2022)
2 years ago by @bijbecgjournal
show all tags
Sustainable
disclosure
finance
financialservicessector
information
nonfinancial
regulation
sustainablefinanceplatform
sustainableinvestment
Sustainabledisclosurefinancefinancialservicessectorinformationnonfinancialregulationsustainablefinanceplatformsustainableinvestment
(0)
copydeleteadd this publication to your clipboard
1Environmental Sustainability Accounting and the Performance of Oil and Gas Companies in Rivers State, Nigeria
I. Okpobo. INTERNATIONAL JOURNAL OF TREND IN SCIENTIFIC RESEARCH AND DEVELOPMENT, 6 (5): 1391-1401 (August 2022)
2 years ago by @ijtsrd
show all tags
Community
disclosure
environmental
humans
issues
resources
sustainability
Communitydisclosureenvironmentalhumansissuesresourcessustainability
(0)
copydeleteadd this publication to your clipboard
1Impact of Green Accounting Disclosures on Sustainability of Manufacturing Firms in Nigeria
O. C. INTERNATIONAL JOURNAL OF TREND IN SCIENTIFIC RESEARCH AND DEVELOPMENT, 6 (2): 827-837 (February 2022)
2 years ago by @ijtsrd
show all tags
&
Control
Disclosure
Environmental
Management
Pollution
Remediation
Sustainability
Waste
&ControlDisclosureEnvironmentalManagementPollutionRemediationSustainabilityWaste
(0)
copydeleteadd this publication to your clipboard
1Social Sustainability Disclosures and Performance of ICT Firms in Nigeria an Independent and Joint Effect Analysis
O. N. INTERNATIONAL JOURNAL OF TREND IN SCIENTIFIC RESEARCH AND DEVELOPMENT, 6 (1): 1356-1365 (December 2021)
2 years ago by @ijtsrd
show all tags
&
Decent
Disclosure
Firms
Human
Labour
Performance
Practice
Product
Responsibility
Rights
Social
Societal
Sustainability
Work
&DecentDisclosureFirmsHumanLabourPerformancePracticeProductResponsibilityRightsSocialSocietalSustainabilityWork
(0)
copydeleteadd this publication to your clipboard
1Board Attributes and Sustainability Disclosure of Quoted Companies in the Building Material Sub Sector of Nigeria
E. S. INTERNATIONAL JOURNAL OF TREND IN SCIENTIFIC RESEARCH AND DEVELOPMENT, 6 (1): 877-885 (December 2021)
2 years ago by @ijtsrd
show all tags
Board
Diligence
Disclosure
Stakeholder’s
Sustainability
independence
size
theory
BoardDiligenceDisclosureStakeholder’sSustainabilityindependencesizetheory
(0)
copydeleteadd this publication to your clipboard
1Effect of Voluntary Disclosure on Corporate Performance of Quoted Manufacturing Companies in Nigeria
J. Ikemefuna, Victor C. | Onuora. International Journal of Trend in Scientific Research and Development, 5 (4): 1308-1314 (June 2021)
3 years ago by @ijtsrd
show all tags
NPM
ROA
ROE
Voluntary
and
disclosure
NPMROAROEVoluntaryanddisclosure
(0)
copydeleteadd this publication to your clipboard

⟨⟨
⟨
1
2
3
⟩
⟩⟩

BibSonomy

bookmarks (hide)2
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

1Disclosure - Wikipedia, the free encyclopedia

1Blogging Ethics: When And What Should Bloggers Disclose?

publications (hide)52
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...

1Corporate Information Disclosure and Stock Market Valuation? A Dummy Variable Regresssion Approach

1Board Characteristics and Environmental Remediation Disclosure of Listed Oil and Gas Firms in Nigeria and South Africa

1Leaping to conclusions.

1Reformulating the hazard ratio to enhance communication with clinical investigators.

1Varieties of uncertainty and the validity of informed consent.

1Medicine. Moving toward transparency of clinical trials.

1Design of clinical trials.

1Research protocols: waiving confidentiality for the greater good.

2The ADVANTAGE seeding trial: a review of internal documents.

1The continuing unethical conduct of underpowered clinical trials.

1Declaration of transparency for each research article.

1The influence of money on medical science.

1Genetic and molecular epidemiology.

1Guidelines for reporting mortality and morbidity after cardiac valve interventions.

1The Ripple Effect of EU Disclosures Regulation in Financial Services Sector

1Environmental Sustainability Accounting and the Performance of Oil and Gas Companies in Rivers State, Nigeria

1Impact of Green Accounting Disclosures on Sustainability of Manufacturing Firms in Nigeria

1Social Sustainability Disclosures and Performance of ICT Firms in Nigeria an Independent and Joint Effect Analysis

1Board Attributes and Sustainability Disclosure of Quoted Companies in the Building Material Sub Sector of Nigeria

1Effect of Voluntary Disclosure on Corporate Performance of Quoted Manufacturing Companies in Nigeria

browse

related tags

similar tags

bookmarks (hide)2 displayallbookmarks onlybookmarks per page5102050100 sort byadded attitle RSSBibTeXXML

publications (hide)52 displayallpublications onlypublications per page5102050100 sort byadded attitleauthorpublication dateentry typehelp for advanced sorting... RSSBibTeXRDFmore...

browse

related tags

similar tags

bookmarks (hide)2
display
all
bookmarks only
bookmarks per page
5
10
20
50
100
sort by
added at
title
RSS
BibTeX
XML

publications (hide)52
display
all
publications only
publications per page
5
10
20
50
100
sort by
added at
title
author
publication date
entry type
help for advanced sorting...
RSS
BibTeX
RDF
more...